ArticleLeukemia2020
Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy.
Abstract readLetter
In one paragraph
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Adverse Effects of Low Serum HDL-C Levels on Prognosis and Tumor Immune Microenvironment in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia.Cancer medicine · 2026Article
- Chronic Lymphocytic Leukemia: Investigation of Survival and Prognostic Factors with Drug-Related Remission.Diagnostics (Basel, Switzerland) · 2025Article
- The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis.Annals of hematology · 2023Article
- The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019.Biomedical engineering online · 2022Article
- Tspan18 is a novel regulator of thrombo-inflammation.Medical microbiology and immunology · 2020Review
- Recent Advances in Allogeneic CAR-T Cells.Biomolecules · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Moritz FürstenauDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany. moritz.fuerstenau@uk-koeln.de.
Georg HopfingerDepartment of Internal Medicine I, Bone Marrow Transplantation, Medical University of Vienna, Vienna, Austria.
Sandra RobrechtDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Anna-Maria FinkDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Othman Al-SawafDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0001-9895-0570
Petra LangerbeinsDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Paula CramerDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Julia Von TresckowDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Christian MaurerDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Nadine KutschDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Manuela HoechstetterDepartment of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, München Klinik Schwabing, Munich, Germany.
Martin DreylingDepartment of Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Elisabeth LangeEvangelisches Krankenhaus Hamm, Hamm, Germany.
Michael KnebaDepartment II of Internal Medicine, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Stephan StilgenbauerDepartment of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
Hartmut DöhnerDepartment of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
Manfred HenselMannheim Oncology Practice, Mannheim, Germany.
Michael G KiehlDepartment of Internal Medicine, Frankfurt (Oder) General Hospital, Frankfurt/Oder, Germany.
Ulrich JaegerDepartment of Medicine I, Clinical Division of Hematology and Hemostaseology and Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.
Clemens-Martin WendtnerDepartment of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, München Klinik Schwabing, Munich, Germany.
Valentin GoedeOncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital, Cologne, Germany.
Kirsten FischerDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Michael von Bergwelt-BaildonDepartment of Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Barbara EichhorstDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Michael HallekDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Sebastian TheurichDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany. sebastian.theurich@med.uni-muenchen.de.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideClinical Trials, Phase III as TopicFemaleFollow-Up StudiesHumansImmunotherapyLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedObesityPrognosisProspective StudiesBendamustine HydrochlorideRituximabVidarabine
Identifiers
PMID
31728057What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.